Cargando…

Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy

BACKGROUND: There are limited data on the long-term adverse clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease (MAFLD). METHODS: This is a single-centre prospective study of a well-characterized cohort of MAFLD patients who underwent liver biopsy and followed every...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Wah-Loong, Chong, Shi-En, Chang, Felicia, Lai, Lee-Lee, Chuah, Kee-Huat, Nik Mustapha, Nik Raihan, Mahadeva, Sanjiv, Chan, Wah-Kheong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218774/
https://www.ncbi.nlm.nih.gov/pubmed/37237087
http://dx.doi.org/10.1007/s12072-023-10550-9
_version_ 1785048853696741376
author Chan, Wah-Loong
Chong, Shi-En
Chang, Felicia
Lai, Lee-Lee
Chuah, Kee-Huat
Nik Mustapha, Nik Raihan
Mahadeva, Sanjiv
Chan, Wah-Kheong
author_facet Chan, Wah-Loong
Chong, Shi-En
Chang, Felicia
Lai, Lee-Lee
Chuah, Kee-Huat
Nik Mustapha, Nik Raihan
Mahadeva, Sanjiv
Chan, Wah-Kheong
author_sort Chan, Wah-Loong
collection PubMed
description BACKGROUND: There are limited data on the long-term adverse clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease (MAFLD). METHODS: This is a single-centre prospective study of a well-characterized cohort of MAFLD patients who underwent liver biopsy and followed every 6–12 months for adverse clinical outcomes. RESULTS: The data for 202 patients were analyzed [median age 55.0 (48.0–61.3) years old; male, 47.5%; obese, 88.6%; diabetes mellitus, 71.3%; steatohepatitis, 76.7%; advanced fibrosis, 27.2%]. The median follow-up interval was 7 (4–8) years. The cumulative incidence of liver-related events, cardiovascular events, malignancy and mortality was 0.43, 2.03, 0.60 and 0.60 per 100 person-years of follow-up, respectively. Liver-related events were only seen in patient with advanced fibrosis at 9.1% vs 0% in patient without advanced liver fibrosis (p < 0.001). The cumulative incidence of liver-related events among patients with advanced fibrosis was 1.67 per 100 person-years of follow-up. When further stratified to bridging fibrosis and cirrhosis, the cumulative incidence of liver-related events was 1.47 and 3.85 per 100 person-years of follow-up, respectively. Advanced fibrosis was not significantly associated with cardiovascular events, malignancy or mortality. The cumulative incidence of liver-related events, cardiovascular events, malignancy and mortality were not significantly different between patients with and without steatohepatitis and between obese and non-obese patients. However, liver-related events were only seen among obese patients. CONCLUSION: Overall, the cumulative incidence of liver-related event is low in patients with MAFLD, but it is much higher among those with advanced fibrosis. However, there is a relatively high cumulative incidence of cardiovascular event among patients with MAFLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-023-10550-9.
format Online
Article
Text
id pubmed-10218774
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-102187742023-05-30 Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy Chan, Wah-Loong Chong, Shi-En Chang, Felicia Lai, Lee-Lee Chuah, Kee-Huat Nik Mustapha, Nik Raihan Mahadeva, Sanjiv Chan, Wah-Kheong Hepatol Int Original Article BACKGROUND: There are limited data on the long-term adverse clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease (MAFLD). METHODS: This is a single-centre prospective study of a well-characterized cohort of MAFLD patients who underwent liver biopsy and followed every 6–12 months for adverse clinical outcomes. RESULTS: The data for 202 patients were analyzed [median age 55.0 (48.0–61.3) years old; male, 47.5%; obese, 88.6%; diabetes mellitus, 71.3%; steatohepatitis, 76.7%; advanced fibrosis, 27.2%]. The median follow-up interval was 7 (4–8) years. The cumulative incidence of liver-related events, cardiovascular events, malignancy and mortality was 0.43, 2.03, 0.60 and 0.60 per 100 person-years of follow-up, respectively. Liver-related events were only seen in patient with advanced fibrosis at 9.1% vs 0% in patient without advanced liver fibrosis (p < 0.001). The cumulative incidence of liver-related events among patients with advanced fibrosis was 1.67 per 100 person-years of follow-up. When further stratified to bridging fibrosis and cirrhosis, the cumulative incidence of liver-related events was 1.47 and 3.85 per 100 person-years of follow-up, respectively. Advanced fibrosis was not significantly associated with cardiovascular events, malignancy or mortality. The cumulative incidence of liver-related events, cardiovascular events, malignancy and mortality were not significantly different between patients with and without steatohepatitis and between obese and non-obese patients. However, liver-related events were only seen among obese patients. CONCLUSION: Overall, the cumulative incidence of liver-related event is low in patients with MAFLD, but it is much higher among those with advanced fibrosis. However, there is a relatively high cumulative incidence of cardiovascular event among patients with MAFLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12072-023-10550-9. Springer India 2023-05-26 /pmc/articles/PMC10218774/ /pubmed/37237087 http://dx.doi.org/10.1007/s12072-023-10550-9 Text en © Asian Pacific Association for the Study of the Liver 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Chan, Wah-Loong
Chong, Shi-En
Chang, Felicia
Lai, Lee-Lee
Chuah, Kee-Huat
Nik Mustapha, Nik Raihan
Mahadeva, Sanjiv
Chan, Wah-Kheong
Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
title Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
title_full Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
title_fullStr Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
title_full_unstemmed Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
title_short Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
title_sort long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218774/
https://www.ncbi.nlm.nih.gov/pubmed/37237087
http://dx.doi.org/10.1007/s12072-023-10550-9
work_keys_str_mv AT chanwahloong longtermclinicaloutcomesofadultswithmetabolicdysfunctionassociatedfattyliverdiseaseasinglecentreprospectivecohortstudywithbaselineliverbiopsy
AT chongshien longtermclinicaloutcomesofadultswithmetabolicdysfunctionassociatedfattyliverdiseaseasinglecentreprospectivecohortstudywithbaselineliverbiopsy
AT changfelicia longtermclinicaloutcomesofadultswithmetabolicdysfunctionassociatedfattyliverdiseaseasinglecentreprospectivecohortstudywithbaselineliverbiopsy
AT laileelee longtermclinicaloutcomesofadultswithmetabolicdysfunctionassociatedfattyliverdiseaseasinglecentreprospectivecohortstudywithbaselineliverbiopsy
AT chuahkeehuat longtermclinicaloutcomesofadultswithmetabolicdysfunctionassociatedfattyliverdiseaseasinglecentreprospectivecohortstudywithbaselineliverbiopsy
AT nikmustaphanikraihan longtermclinicaloutcomesofadultswithmetabolicdysfunctionassociatedfattyliverdiseaseasinglecentreprospectivecohortstudywithbaselineliverbiopsy
AT mahadevasanjiv longtermclinicaloutcomesofadultswithmetabolicdysfunctionassociatedfattyliverdiseaseasinglecentreprospectivecohortstudywithbaselineliverbiopsy
AT chanwahkheong longtermclinicaloutcomesofadultswithmetabolicdysfunctionassociatedfattyliverdiseaseasinglecentreprospectivecohortstudywithbaselineliverbiopsy